Purification and characterization of recombinant neuraminidase as a potentially broadly protective influenza virus vaccine candidate
Influenza viruses pose a significant public health threat, causing seasonal epidemics and occasional pandemics with substantial morbidity and mortality worldwide.
Global immunisation monitoring in times of drastic cutbacks
Outbreaks of vaccine-preventable diseases are increasing at a time when funding for immunisation programmes is being cut.
Immunogenicity and protective efficacy of an intranasal neuraminidase-based influenza vaccine with bacterial cell membrane-derived adjuvants
Recombinant neuraminidase (NA) has emerged as an antigenically conserved intranasal vaccine candidate, capable of inducing broad cross-protection, but it requires effective mucosal adjuvants.
News
Policy & Recommendations
The fight against disinformation on health issues in the EU
Croatia, Estonia, France, Germany, Lithuania, Slovenia and Spain produced an information note highlighting the loss of confidence in science and health authorities, representing a major challenge for democracies.
Immunogenicity of inactivated quadrivalent influenza vaccine in pregnant women, including the level of postvaccination antibodies in umbilical cord blood
It is necessary to increase knowledge about the safety and effectiveness of influenza vaccination during pregnancy to improve awareness among patients and healthcare professionals and increase to increase vaccination coverage.
Comparative effectiveness of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) in children over multiple influenza seasons (2019–2023)
Annual vaccination with LAIV4 or IIV4 remains the best way to protect children against influenza infection.
Advisory Committee on Immunization Practices at a Crossroads
Recent scientific advancements enabled the accelerated development, production, and evaluation of COVID-19 vaccines, leveraging novel technologies that are estimated to have prevented approximately 1.6 million hospitalizations and 235.000 deaths in the US
Respiratory syncytial virus vaccine effectiveness among US veterans, September, 2023 to March, 2024: a target trial emulation study
New respiratory syncytial virus (RSV) vaccines have been approved in the USA for the prevention of RSV-associated lower respiratory tract disease in adults aged 60 years and older.
